IMCC
IM Cannabis Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$1.98
−10.00%Year over year
Reported trailing growth
- Revenue
- -21.1%
- EBITDA
- —
- EBIT
- +43.3%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +37.6%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.2%
- EBITDA
- -13.1%
- EBIT
- -13.2%
- Net income
- -6.9%
- EPS
- +40.8%
- Free cash flow
- +481.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026